Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin in the treatment of schizophrenia
IRCT201202251556N35Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin in schizophrenia, sponsored by Tehran University of Medical Sciences. Started Jan 2012; status: completed.
02
Drugs
oxytocin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT201202251556N35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201202251556N35.